Table 2.
Effects of F2, and ERK1/2 inhibitors and activator on LDH level, cTnI level, and cell viability in extracellular-calcium-free myocardial H/R (n = 9).
| Group | LDH (U/mL) | cTnI (ng/mL) | Survival rate (%) |
|---|---|---|---|
| 0CaCon | 968.65 ± 12.37 | 0.17 ± 0.01 | 100.00 |
| 0CaH/R | 1342.35 ± 15.82* | 0.84 ± 0.03* | 50.66 ± 1.90* |
| 0CaH/R + F2 | 1135.16 ± 22.33∗# | 0.62 ± 0.04∗# | 67.38 ± 2.94∗# |
| 0CaH/R + U0126 | 1155.04 ± 24.24∗# | 0.69 ± 0.03∗# | 62.81 ± 4.58∗# |
| 0CaH/R + PD98059 | 1261.39 ± 14.20∗# | 0.53 ± 0.02∗#† | 57.73 ± 2.71∗# |
| 0CaCon + EGF | 1019.90 ± 17.16#† | 0.17 ± 0.01#† | 94.01 ± 4.70#† |
| 0CaH/R + F2 + EGF | 1421.43 ± 17.16∗† | 0.77 ± 0.05∗† | 53.17 ± 2.48∗† |
F2, N-n-butyl haloperidol iodide; LDH: lactate dehydrogenase; cTnI: cardiac troponin I; H/R: hypoxia/reoxygenation. *P < 0.05 versus 0CaCon group; # P < 0.05 versus 0CaH/R group; † P < 0.05 versus 0CaH/R + F2 group.